

NEW, LOWER TAXOTERE® PRICES FOR ONCOLOGY ASSOCIATES MEMBERS!

Oncology Associates is pleased to announce a new agreement with **Aventis**, effective February 15, 2004. This agreement will enable OA Members to receive the maximum discounting structure available for **Taxotere®**.

Contract Terms: February 15, 2004 to June 30, 2004

Your current contract price is based on all Taxotere® purchases between January 1, 2003 to June 30, 2003. This transition period of the new contract sets standardized discounts, regardless of prior market share performance.

1. OA Members who purchased **less** than \$500,000 of Taxotere® will receive a contract price of 10% below WAC.
2. OA Members who purchased **more** than or equal to \$500,000 of Taxotere® will receive a contract price of 13% below WAC.

Product	NDC
Taxotere® 20 mg Sol	00075-8001-20
Taxotere® 80 mg Sol	00075-8001-80

Contract Terms: July 1, 2004 to December 31, 2005

- Discounts below WAC will be based on your Taxotere® purchases as a percentage of your practice's total combined purchases of Taxotere®, Paclitaxel, and Gemcitabine measured in equivalent dosing units.
- Individual practice performance will be measured each calendar quarter according to the schedule listed below.
- **Data must be reported by practices on a quarterly basis on the Aventis web site by deadlines specified below.** More details to follow from OA on this topic.

Measurement Period	Reporting Deadline	Practice Specific Contract Price Start Date
01/01/04 – 03/31/04	05/15/04	07/01/04 – 09/30/04
04/01/04 – 06/30/04	08/15/04	10/01/04 – 12/31/04
07/01/04 – 09/30/04	11/15/04	01/01/05 – 03/31/05

OA Members currently attached to the OA Taxotere® agreement with a signed declaration letter on file were automatically enrolled in the new contract **February 15, 2004**.

For more details about this exciting agreement, contact Oncology Associates at 888-732-7352.